Structure Therapeutics (GPCR) has drawn investor attention after a packed August 6 update that combined second quarter earnings, fresh timelines for aleniglipron clinical data, and the appointment of experienced commercial leader John Berrios.
See our latest analysis for Structure Therapeutics.
At a recent share price of US$54.51, Structure Therapeutics has seen strong momentum in recent months, with a 30 day share price return of 12.44% and a 90 day share price return of 51.92%. However, the year to date share price return is down 19.98% and the 1 year total shareholder return is 173.10%, which suggests investors have rapidly reassessed both the growth potential of its obesity pipeline and the risks highlighted by wider quarterly losses and the latest clinical timelines.
If the aleniglipron updates have your attention and you want to see where else the market is pricing in ambitious growth stories, take a look at 40 healthcare AI stocks
Structure Therapeutics has already priced in a lot of excitement after the recent move, yet the next major aleniglipron readouts are scheduled for 2026. Do you maintain exposure at the current price or wait for a pullback before those milestones?
Preferred Price to Book Multiple of 2.9x: Is it justified for Structure Therapeutics?
On a P/B of 2.9x at a share price of $54.51, Structure Therapeutics sits below the 6.2x peer average but above the 2.5x US pharmaceuticals industry level, which sends a mixed signal on valuation.
P/B compares the stock price to the company’s net assets on the balance sheet, so it can be a useful cross check for a business like Structure Therapeutics that is still loss making and has limited current revenue. In this case, the data suggests investors are paying less than the average of direct peers for each dollar of book value, even though the company reported a loss of $214.835m and currently generates no revenue.
At the same time, the P/B of 2.9x sits higher than the broader US pharmaceuticals industry average of 2.5x. That implies the market is assigning some premium to Structure Therapeutics relative to the wider sector, likely reflecting expectations around its clinical pipeline and the strong 1 year total shareholder return that has outpaced both the US market and the pharmaceuticals group.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 2.9x (ABOUT RIGHT)
However, investors in Structure Therapeutics still face clear risks, including the possibility of clinical setbacks and the company’s ongoing losses with no current revenue base.
Find out about the key risks to this Structure Therapeutics narrative.
Next Steps
If this Structure Therapeutics update leaves you with mixed feelings, that is the point. Take time while the details are fresh in your mind to consider both perspectives and use the 1 key reward and 4 important warning signs
Looking for more investment ideas beyond Structure Therapeutics?
If you want to keep strengthening your portfolio, do not stop at Structure Therapeutics. Use targeted stock lists to uncover other opportunities that fit your goals.
- Target potential mispricings by scanning for companies that combine strong fundamentals with appealing valuations through the 53 high quality undervalued stocks.
- Build a steadier income stream by reviewing companies that offer robust yields and payment records using the 10 dividend fortresses.
- Prioritise resilience by searching for companies with stronger financial footing and lower risk profiles via the 80 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com